Personalized immunotherapy treatments help 90% of acute lymphoblastic leukemia patients achieve remission in a new study.

Boehringer Ingelheim's OFEV was approved by FDA as the first treatment for idiopathic pulmonary fibrosis, a fatal lung disease.

Genentech announced FDA-approved Esbriet for the treatment of Idiopathic Pulmonary Fibrosis.

Pfizer's addition of a new vaccine suite and multiproduct bioprocess suite to its Ireland facility win the company the title of 2014 Facility of the Year.

The company submits an orphan drug application to FDA for its Cell-in-a-Box treatment for pancreatic cancer.

Sanofi Pasteur and Immune Design agree to jointly develop therapies through Phase II clinical trials.

BioReliance has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services its service offering. The company#&39;s range of predictive assays use a novel suite of genetically modified cell lines created with CompoZr zinc finger nuclease (ZFN), a Sigma-Aldrich proprietary technology.

AbbVie sends Shire notice that it is reconsidering its offer recommendation.

The International Society for Pharmaceutical Engineering (ISPE) released its Drug Shortages Prevention Plan as part of an initiative to address drug shortage prevention due to manufacturing and quality issues.

Hospira voluntary recalls certain lots of several LifeCare products due to potential for leakage.

The Pharmaceutical Research and Manufacturers of America released their 2014 Cancer Report that highlights the biopharmaceutical companies developing new medicines and vaccines used for the treatment of cancer.

A report from PhRMA highlights how drugs that failed in clinical trials are a crucial part of development for melanoma, lung cancer, and brain cancer.

Pfizer announced that it has received FDA Priority Review for palbociclib, in combination with letrozole, as a treatment for HER2- advanced breast cancer.

IDT Biologika completes large-scale biologics finishing facility in Dessau, Germany.

Iclusig?s original indication will remain unchanged after a thorough examination of its safety information by EMA.

The European Medicines Agency releases highlights from its Pharmacovigilance Risk Assessment Committee safety review meeting in October.

Endo will acquire Auxilium Pharmaceuticals in a cash and stock transaction for approximately $2.6 billion.

CPhI released Part 3 of its annual industry report featuring three experts in the pharmaceutical industry.

FDA granted Genentech priority review for its diabetic retinopathy treatment, Lucentis.

The National Institutes of Health announces grants for the development of strategies for the utilization of biomedical data sets.

New polymers from Dow presented at CPhI 2014 help maximize a pharmaceutical product's solubilization performance.

New investments, expansions, and company rebranding are discussed at CPhI.

Colorcon announced that it will cooperate with BASF to add Kollicoat IR immediate-release coating polymer to Colorcon's film-coating portfolio.

CPhI released Part 2 of its annual industry report focused on the future of the pharmaceutical industry.

West Pharmaceutical Services will be showcasing its portfolio of drug packaging and delivery system solutions at CPhI this year.

BD announces agreement to acquire CareFusion to further medication management and patient safety solutions.

Celebrating the best of pharma and recognizing companies that turn inspiration into innovation.

FDA outlines procedures for having a Critical Path Innovation Meeting with CDER.